Erdafitinib / Pemigatinib / Futibatinib
Approved, for something elseMeasured in people, not heightBy mouthSmall molecule
Three approved cancer drugs that switch off a whole family of growth-signal receptors at once.
Three pan-FGFR kinase inhibitors, all of them approved cancer drugs. They inhibit multiple FGFR isoforms, preventing receptor trans-autophosphorylation. Erdafitinib and pemigatinib bind reversibly; futibatinib covalently and irreversibly.
Risks. They are cancer drugs and they do cancer-drug damage: fluid under the retina in a fifth of patients, phosphate high enough in three quarters of them to risk calcium depositing in soft tissue, and nail damage in seven out of ten.
On this page
- At the growth plate, members only
- Risks and side effects, members only
The rest of this page is for members
What has been measured, in whom, with every source, and what it does to the rest of you. And every article in the library.
Join for $11.99Lifetime · 3 of 10 founding spots left
Tax is added at checkout (VAT/GST where it applies).
Renews every month at the current price plus tax until you cancel. Cancel from your account before the next monthly charge to stop it.
Card purchases are sold and charged by Link (Stripe) under Link's terms and refund policy.
Already a member? Sign in
Educational content, not medical advice. Nothing here is a recommendation to take or stop taking anything — talk to a doctor about your own situation.